Anti-VEGF nel trattamento della retinopatia diabetica

Translated title of the contribution: Anti-VEGF approach in the treatment of diabetic retinopathy

Research output: Contribution to journalArticle

Abstract

The most common causes of vision loss in patients affected by diabetes mellitus are represented by diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). The global burden of diabetic retinopathy (DR) requires special care owing to its high impact on public health and on quality of life of patients. At present, laser retinal photocoagulation is still the standard of care for the management of DR. However, laser treatment have shown clear limitations, reducing the risk of moderate visual loss by approximately 50%, with no remarkable vision recovery. Thus, new approaches in the treatment of DR have been tried, including the therapy based on anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as endothelial cell-specific mitogen and vasopermeability factor. Through these mechanisms the VEGF has a critical role in promoting the angiogenesis and vascular leakage in DR. Main anti-VEGF molecules which have been recently studied for the treatment of DR include pegaptanib, ranibizumab, and bevacizumab. In the present review, the results of the anti-VEGF therapy in the treatment of the DME and PDR are described and discussed.

Original languageItalian
Pages (from-to)82-87
Number of pages6
JournalGiornale Italiano di Diabetologia e Metabolismo
Volume31
Issue number2
Publication statusPublished - 2011

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Macular Edema
Therapeutics
Lasers
Light Coagulation
Standard of Care
Mitogens
Blood Vessels
Intercellular Signaling Peptides and Proteins
Diabetes Mellitus
Endothelial Cells
Public Health
Quality of Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Anti-VEGF nel trattamento della retinopatia diabetica. / Bandello, F.; Iacono, P.; Battaglia Parodi, M.

In: Giornale Italiano di Diabetologia e Metabolismo, Vol. 31, No. 2, 2011, p. 82-87.

Research output: Contribution to journalArticle

@article{210adc558f514fb7b4c1df405ebc8dec,
title = "Anti-VEGF nel trattamento della retinopatia diabetica",
abstract = "The most common causes of vision loss in patients affected by diabetes mellitus are represented by diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). The global burden of diabetic retinopathy (DR) requires special care owing to its high impact on public health and on quality of life of patients. At present, laser retinal photocoagulation is still the standard of care for the management of DR. However, laser treatment have shown clear limitations, reducing the risk of moderate visual loss by approximately 50{\%}, with no remarkable vision recovery. Thus, new approaches in the treatment of DR have been tried, including the therapy based on anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as endothelial cell-specific mitogen and vasopermeability factor. Through these mechanisms the VEGF has a critical role in promoting the angiogenesis and vascular leakage in DR. Main anti-VEGF molecules which have been recently studied for the treatment of DR include pegaptanib, ranibizumab, and bevacizumab. In the present review, the results of the anti-VEGF therapy in the treatment of the DME and PDR are described and discussed.",
keywords = "Anti-vascular endothelial growth factor, Bevacizumab, Diabetic retinopathy, Pagaptanib, Ranibizumab",
author = "F. Bandello and P. Iacono and {Battaglia Parodi}, M.",
year = "2011",
language = "Italian",
volume = "31",
pages = "82--87",
journal = "Giornale Italiano di Diabetologia",
issn = "1593-6104",
publisher = "UTET Periodici Scientifici srl",
number = "2",

}

TY - JOUR

T1 - Anti-VEGF nel trattamento della retinopatia diabetica

AU - Bandello, F.

AU - Iacono, P.

AU - Battaglia Parodi, M.

PY - 2011

Y1 - 2011

N2 - The most common causes of vision loss in patients affected by diabetes mellitus are represented by diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). The global burden of diabetic retinopathy (DR) requires special care owing to its high impact on public health and on quality of life of patients. At present, laser retinal photocoagulation is still the standard of care for the management of DR. However, laser treatment have shown clear limitations, reducing the risk of moderate visual loss by approximately 50%, with no remarkable vision recovery. Thus, new approaches in the treatment of DR have been tried, including the therapy based on anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as endothelial cell-specific mitogen and vasopermeability factor. Through these mechanisms the VEGF has a critical role in promoting the angiogenesis and vascular leakage in DR. Main anti-VEGF molecules which have been recently studied for the treatment of DR include pegaptanib, ranibizumab, and bevacizumab. In the present review, the results of the anti-VEGF therapy in the treatment of the DME and PDR are described and discussed.

AB - The most common causes of vision loss in patients affected by diabetes mellitus are represented by diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). The global burden of diabetic retinopathy (DR) requires special care owing to its high impact on public health and on quality of life of patients. At present, laser retinal photocoagulation is still the standard of care for the management of DR. However, laser treatment have shown clear limitations, reducing the risk of moderate visual loss by approximately 50%, with no remarkable vision recovery. Thus, new approaches in the treatment of DR have been tried, including the therapy based on anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as endothelial cell-specific mitogen and vasopermeability factor. Through these mechanisms the VEGF has a critical role in promoting the angiogenesis and vascular leakage in DR. Main anti-VEGF molecules which have been recently studied for the treatment of DR include pegaptanib, ranibizumab, and bevacizumab. In the present review, the results of the anti-VEGF therapy in the treatment of the DME and PDR are described and discussed.

KW - Anti-vascular endothelial growth factor

KW - Bevacizumab

KW - Diabetic retinopathy

KW - Pagaptanib

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=82555179307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555179307&partnerID=8YFLogxK

M3 - Articolo

VL - 31

SP - 82

EP - 87

JO - Giornale Italiano di Diabetologia

JF - Giornale Italiano di Diabetologia

SN - 1593-6104

IS - 2

ER -